Lexicon Pharmaceuticals vs Zymeworks
Zymeworks is the larger business, with $106m of revenue in fiscal 2025 against $49.8m for Lexicon Pharmaceuticals (2.1 times as much). Lexicon Pharmaceuticals grew faster (60.2% against 38.9%). Zymeworks kept more of each dollar of sales as profit: a net margin of -76.6% against -101.1%. Zymeworks carries less debt relative to equity (0.0% against 50.2%).
| Latest fiscal year | Lexicon PharmaceuticalsLXRX, 2025 | ZymeworksZYME, 2025 |
|---|---|---|
| Revenue | $49.8m | $106m |
| Revenue growth | 60.2% | 38.9% |
| Net income | −$50.3m | −$81.1m |
| Operating margin | -98.2% | -87.3% |
| Net margin | -101.1% | -76.6% |
| Return on equity | -39.7% | -26.7% |
| Free cash flow | −$67.9m | −$34.5m |
| Cash | $34.3m | $41.2m |
| Total debt | $54.0m | $0 |
| Debt to equity | 50.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $41.7m |
| Employees | — | 264 |
| Market value | $652m | $2.16bn |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | — |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 11 sales |